Literature DB >> 20486745

Predictive baseline criteria of primary therapeutic failure in chronic hepatitis C genotype 1.

F Cuenca1, C Fernández, M J Devesa, G López-Alonso, J Mayol, A Suárez, L Ortega, M Díaz-Rubio, J M Ladero.   

Abstract

BACKGROUND AND AIMS: more than half of patients with genotype 1 chronic hepatitis C (CHC) do not achieve a sustained viral response (SVR) to current antiviral therapy due to primary non-response, relapse or intolerance. Factors related to each of these unfavorable outcomes are different and the last two may be partially prevented. Our aim was to identify basal criteria to predict the risk of primary failure. PATIENTS AND METHODS: we included 251 consecutive patients (152 males) from a single centre, infected with HCV genotype 1 and not previously treated. SVR was achieved in 141 patients and primary failure in 110.
RESULTS: high vs. low viral load (> 400,000 IU/mL, OR = 6.17; 95% CI: 2.50-15.23), high serum GGT (> 60 IU/mL, OR = 4.25; 95% CI: 2.49-7.24), low serum cholesterol ( < 178 mg/dL, OR = 2.93; 95% CI: 1.75-4.92) and older age (> 47 yrs., OR = 1.79; 95% CI: 1.08-2.96) were associated to the risk of primary failure in the lineal logistic regression analysis. From the 58 patients carrying all the first three negative criteria, 46 (79.3%) were primary non-responders.
CONCLUSIONS: the negative basal profile identified in this study is based on easily available data and provides information about the risk of primary therapeutic failure, and may help to decide whether antiviral therapy should be offered to a single patient.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20486745     DOI: 10.4321/s1130-01082010000400003

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  3 in total

1.  Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease.

Authors:  José A Agúndez; Elena García-Martin; María L Maestro; Francisca Cuenca; Carmen Martínez; Luis Ortega; Miguel Carballo; Marta Vidaurreta; Marta Agreda; Gabriela Díaz-Zelaya; Avelina Suárez; Manuel Díaz-Rubio; José M Ladero
Journal:  PLoS One       Date:  2012-05-29       Impact factor: 3.240

2.  Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C.

Authors:  Elena García-Martín; José A G Agúndez; María L Maestro; Avelina Suárez; Marta Vidaurreta; Carmen Martínez; Cristina Fernández-Pérez; Luis Ortega; José M Ladero
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

3.  A lower serum gamma-glutamyltransferase level does not predict a sustained virological response in patients with chronic hepatitis C genotype 1.

Authors:  Fatih Güzelbulut; Mesut Sezikli; Züleyha Akkan Cetinkaya; Selvinaz Ozkara; Can Gönen; Ayşe Oya Kurdaş Ovünç
Journal:  Gut Liver       Date:  2012-11-13       Impact factor: 4.519

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.